Editor in Chief Dr KK Aggarwal, Padma Shri Awardee Dated:25 April,2020
Oxford Covid-19 vaccine trial on 510 humans from today
LONDON: The Covid-19 vaccine being developed by the University of Oxford will be tested on hundreds of humans in Britain from Thursday, UK health secretary Matt Hancock announced on Tuesday.
Indian Govt. brings ordinance making attack on doctors, paramedic staff a non-bailable offence punishable with up to 7 years imprisonment
Doctors, paramedics, and other healthcare professionals are “frontline warriors” in this war against COVID-19. Yet, they have been subject to violence and discrimination. The incidents of violence targeting doctors, nurses, healthcare workers are increasing even as they have been engaged in carrying out their duties....read more
CMAAO Coronavirus Facts and Myth Buster 70
(With regular inputs from Dr Monica Vasudev)
Debts in Mythology
It is said that there are three debts, which everybody has to pay in his or her lifetime. In Vedic language, they are called Dev Rin, Pitra Rin and Rishi Rin.
Health Sutras By Dr K K Aggarwal
Not using mask when cough and cold
Healthcare News Monitor
The New Indian Express- ANI
The Chairman of Indian Drug Manufacturers' Association, Gujarat chapter has asserted that there is no shortage of Hydroxychloroquine in India and the country's current production of HCQ is 35 to 40 crore tablets a month. Viranchi Shah, Chairman, Indian Drug Manufacturers' Association, Gujarat chapter said, "Our current production capacity of Hydroxychloroquine is 35 to 40 crore tablets a month. This is 10 times more than our requirement. There is no shortage of HCQ in India." He continued saying that India holds almost 70 per cent global capacity of manufacturing HCQ. "Before this COVID-19 situation came into the picture, HCQ was traditionally used for treating Malaria and certain arthritis conditions. If we see the last year's consumption, the total consumption of HCQ in India was about 2.4 crore tablets. Compared to that our current production capacity is almost 34-40 cr tablets a month," said Shah. "India is one of the leading manufacturers in pharmaceuticals. We export medicines to almost every country globally. Even during the lockdown with support of the Modi-government, we have been able to maintain the manufacturing and supply of the medicines. We are also in the position to cater to the international demands of medicines," he added.
Deccan Herald – Kalyan Ray
A medicinally useful microbe discovered by an Indian biologist half-a-century ago has made a comeback in India’s fight against coronavirus as the Council of Scientific and Industrial Research is set to start three clinical trials with a medicine containing an inactivated form of the bacteria. The second trial would on about 500 asymptomatic persons, who may be close contacts of COVID19 patients and health care sta. The objective is to boost their innate immunity and thereby preventing them from acquiring the disease. The third trial will also be on a large number of hospitalised Covid-19 patients who are not critically ill. The aim is to see if the drug can lead to quicker recovery and prevents the disease progression into a more serious one requiring ICU management. “We have received approvals from the Drugs Controller General of India for three trials. The first one will start soon and preliminary results may come in 35-40 days. Depending on the results, we will take a call on the other two trials,” Ram Vishwakarma, director of CSIR-Indian Institute of Integrative Medicine, Jammu and coordinator for the Covid-19 activities at CSIR told DH. At the core of the drug, lies a microbe named Mycobacterium W (MW) that was renamed later as Mycobacterium indicus pranii (MIP) to honour its discoverer Dr Gursaran Pran Talwar – the grand old man of Indian biology – who established the National Institute of Immunology in Delhi. Looking for a vaccine against leprosy, Talwar and his students spotted the MW in the 1970s and extensively studied the germ that was used successfully as a vaccine against leprosy. Because of its several unique properties, other researchers found its utility as a therapy against TB and some form of cancer too several years down the line. The indigenous medicine was developed more than a decade ago in a public-private partnership and the technology was transferred to pharmaceutical major Cadila for commercial manufacturing. The company would now be a part of the trial along with AIIMS, Delhi and Bhopal as well as PGI Chandigarh.
NDTV- Arun Nair
A group of non-resident medical professionals have written an open letter to West Bengal Chief Minister Mamata Banerjee raising concerns over the "gross under-testing" and "misreporting of data" on the cause of death of COVID-19 patients.
Doctors and staff of Lok Nayak Jai Prakash Narain (LNJP) Hospital have alleged that a group of COVID-19 patients who were brought to the hospital through CATS ambulance on Thursday, threatened and manhandled them when the staff asked them to wait for a while.